A novel derivative of the fungal antimicrobial peptide plectasin is active against *Mycobacterium tuberculosis*

Erik Tenland, Nitya Krishnan, Anna Rönnholm, Sadaf Kalsum, Manoj Puthia, Matthias Mörgelin, Mina Davoudi, Magdalena Otrocka, Nader Alarida, Izabela Glegola-Madejska, Erik Sturegård, Artur Schmidt, Maria Lerm, Brian D. Robertson, Gabriela Godaly

**A R T I C L E  I N F O**

**Keywords:**

- *Mycobacterium tuberculosis*
- Antimicrobial peptides
- Tuberculosis treatment

**A B S T R A C T**

Tuberculosis has been reaffirmed as the infectious disease causing most deaths in the world. Co-infection with HIV and the increase in multi-drug resistant *Mycobacterium tuberculosis* strains complicate treatment and increases mortality rates, making the development of new drugs an urgent priority. In this study we have identified a promising candidate by screening antimicrobial peptides for their capacity to inhibit mycobacterial growth. This non-toxic peptide, NZX, is capable of inhibiting both clinical strains of *M. tuberculosis* and an MDR strain at therapeutic concentrations. The therapeutic potential of NZX is further supported in vivo where NZX significantly lowered the bacterial load with only five days of treatment, comparable to rifampicin treatment over the same period. NZX possesses intracellular inhibitory capacity and co-localizes with intracellular bacteria in infected murine lungs. In conclusion, the data presented strongly supports the therapeutic potential of NZX in future anti-TB treatment.

**1. Introduction**

Despite the availability of antibiotics and the extensive use of the live-attenuated vaccine Bacille Calmette-Guérin (BCG), tuberculosis (TB) remains a major health concern with an estimated 10.4 million new cases every year. Current treatment and vaccination programmes have failed to make a significant impact on either transmission or protection against disease, while co-infection with HIV and the emergence of drug resistant strains has further undermined TB control programmes [1,2]. Isoniazid and Rifampicin form an essential part of the standard four-drug treatment for drug-sensitive infections, with a cure rate of 95% under optimal conditions [3]. However, the duration of treatment is long, varying from six months for drug susceptible TB, to more than two years for multi-drug resistant (MDR) TB, where bacteria are resistant to the first-line anti-TB drugs, and extensively drug resistant (XDR) TB in which strains have acquired additional resistance to fluoroquinolone and any one of the three injectable second-line anti-TB drugs [4]. Prolonged treatment contributes to poor patient compliance and the emergence of antibiotic resistance. In 2016, the WHO estimated 600,000 new cases of MDR-TB, of which 6.2% were XDR-TB [5,6].

Antimicrobial peptides (AMPs) have gained interest as potential therapeutics to treat mycobacterial infections. Among the antimicrobial peptides, human defensins and cathelicidins play an important role linking innate and adaptive immune responses [7]. Defensins are a family of naturally occurring cysteine-rich peptides found in higher plants and animals that display activity against a wide variety of microbes, making them attractive drug candidates. The majority of defensins act through disruption of microbial membranes, although they may have additional host-related immune-modulating activities [8]. Most defensins are amphipathic molecules with clusters of positively charged and hydrophobic amino-acid side chains that interact with microbial membranes. It has been proposed that the cationic portion targets the...
peptide to the negatively charged bacterial membrane, while the hydrophobic portion intercalates into the membrane [9,10].

Many naturally occurring AMPs have been tested for activity against *Mycobacterium tuberculosis*, including human and rabbit defensins and porcine protegrins [11-14]. In addition to naturally occurring AMPs, synthetic libraries have been tested for activity against *M. tuberculosis* [15]. Suboptimal efficacy, instability and/or toxicity have so far precluded testing of most AMPs in animal models of *M. tuberculosis* infection. Until now, only the peptides LL-37, innate defense regulators and ecumcin showed significant results in experimental TB murine models after 25–28-days of treatment [16,17]. In this study we investigated NZX, a novel derivative of plectasin, which is the first fungal-derived peptide to the negatively charged bacterial membrane, while the hydrophobic portion intercalates into the membrane [9,10].

We found NZX is proteolytically stable and non-toxic to eukaryotic cells but kills *M. tuberculosis* at concentrations comparable to conventional antibiotics in both in vitro and in vivo models of infection. In the murine TB-model, we found that NZX associated with mycobacteria inside macrophages, and substantially lowered the bacterial load with five days of treatment, comparable to the reduction seen with rifampicin treatment over the same time period.

2. Materials and methods

2.1. Peptides

Four of the investigated peptides were previously reported to possess activity against *M. tuberculosis* in vitro and in vivo (Table 1). LL-37 and the synthetic variants of tryptophan-rich peptides were previously shown to eliminate *M. tuberculosis* at low concentrations in vitro [14,16,20,21]. Plectasin as a potential TB therapeutic although mentioned in the literature has not been tested experimentally to-date [22,23]. NZ2114 is a variant of plectasin, originally isolated from *Pseudoplectania nigrella* [18,24,25]. Numerous publications report NZ2114 to exhibit improved activity compared to plectasin against staphylococci, including *Staphylococcus aureus* as well as *Streptococcus pneumoniae* [18,24,25] (Table 1). The peptide NZX was manufactured by solid phase peptide synthesis, followed by cyclisation of the three naturally occurring disulphide bonds and purification by sequential chromatography steps (PolyPeptide Laboratories AB, Limhamn, Sweden). The peptide NZ2114 was provided by Adenium ApS, Denmark. The purity (97.3%) of the peptides was confirmed by high-performance liquid chromatography.

2.2. Bacteria

For screening experiments and the time kill assay, *Mycobacterium bovis* bacillus Calmette-Guerin (BCG) Montreal containing the pSMT1-luxAB plasmid was prepared as previously described [26]. Briefly, BCG was grown in Middlebrook 7H9 broth, supplemented with 10% ADC enrichment (Middlebrook Albumin Dextrose Catalase Supplement, Becton Dickinson, Oxford, UK) and hygromycin (50 mg/l; Roche, Lewes, UK), the culture was washed twice with sterile PBS, and re-suspended in broth and then dispensed into vials. Glycerol was added to a final concentration of 25% and the vials were frozen at −80 °C. Prior to each experiment, a vial was defrosted, added to 9 ml of 7H9/ADC/hygromycin medium, and incubated with shaking for 72 h at 37 °C. Mycobacteria were then centrifuged for 10 min at 3000 × g, washed twice with PBS, and re-suspended in 10 ml of PBS.

For murine TB experiments, we used *M. tuberculosis* H37Rv with known expression of the surface lipid phosphatidyl dimycocerosate (PDIM) (a kind gift from Christophe Guilhot, Institut de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, France). The strain was cultured to mid-log phase in Middlebrook 7H9 culture medium, supplemented with 0.05% Tween 80, 0.2% glycerol and 10% oleic acid-albumin-dextrose-catalase (OADC) enrichment (Becton Dickinson, Oxford, UK).

In preparation for MIC-determination and electron microscopy studies of the effect of NZX on *M. tuberculosis* in vitro, H37Rv (ATCC 27294) and three clinical strains isolated from pleural effusions (TB216/268 (clinical isolate 1), TB129B (clinical isolate 2) and TB4001 (clinical MDR isolate)) were cultured in MGIT960 according to manufacturer’s instructions. TB4001 is an MDR-TB strain, resistant to Rifampicin and Isoniazid (Supplementary Table 2). The other two strains were fully susceptible to first-line antibiotics and were verified to be *M. tuberculosis* using standard methods at Clinical Microbiology, Regional Laboratories Skåne, Lund, Sweden (data not shown). *Mycobacterium smegmatis* mc²155 (a kind gift from Prof. Leif Kirenbom, Department of Cell and Molecular Biology, Box 596, Biomedical Centre, Uppsala, Sweden).

For the intracellular experiment, *M. tuberculosis* H37Rv (ATCC 27294) transformed with a Live-Dead reporter plasmid [27] was used for infecting primary human macrophages. The bacteria were grown to mid-log phase at 37 °C in Middlebrook 7H9 medium (BD Biosciences, San Diego, CA, USA) with 0.05% Tween-80, 0.05% glycerol and albumin-dextrose-catalase enrichment (ADC, Becton Dickinson) in the presence of 50 μg/ml hygromycin B (Sigma-Aldrich, St Louis, MO) as a selective antibiotic. The bacteria were passaged at 1:9 in the medium and incubated for one more week before use in experiments.

2.3. Cells

Human venous blood mononuclear cells were obtained from healthy volunteers using a Lymphoprep density gradient (Axis-Shield, Oslo, Norway) according to the manufacturer’s instructions. To obtain pure monocytes, CD14 micro beads were applied to the cell suspension, washed and passed through a LS-column according to manufacturer’s description (130-050-201, 130-042-401, Miltenyi Biotech, USA). The monocytes were counted (Sysmex), diluted in RPMI 1640 supplemented with 5% FCS, NEAA, 1 mM Sodium Pyruvate, 0.1 mg/ml Gentamicin (11140-035, 111360-039, 15710-49, Gibco, Life Technologies) and 50 ng/ml GM-CSF (215-GM, R&D systems) and seeded in 96-well plates (10^5/well) for a week to differentiate into macrophages. Infection experiments were performed in RPMI 1640 without Gentamicin.

The human monocyte cell line, THP-1-XBlue™-CD14 (Invivogen, San Diego, CA, USA) were cultured in RPMI 1640 supplemented with 10% FCS, Antibiotic-Antimycotic, Zeocin, and Geneticin (15240062, R25005, 10131035, Gibco, Life Technologies).

2.4. Screening studies

To measure peptide activity against mycobacteria, BCG expressing luxAB was diluted in Middlebrook 7H9 medium (10^4 CFU; 150 μl/well)
in 96-well opaque white plates (Corning). Peptides (0, 6.3, 12.5, 25, 50 or 100 μM) were added to the wells. Growth controls containing no peptide and peptide without bacteria were also prepared. The plates were incubated at 37 °C for 24 h before adding 0.1% n-decyl aldehyde (Decanal, Sigma), a substrate for bacterial luciferase. Bioluminescence was measured as relative luminescence unit (RLU) [26] for 1s using a TriStar® microplate reader (Berthold Technologies).

2.5. Cytotoxicity assays

For the peptide-screening assay, primary macrophages were prepared from whole blood (see above). The medium was replaced with fresh medium containing 0, 6.3, 12.5, 25 or 100 μM peptides and incubated for 0, 1, 4 and 24 h in 5% CO2 atmosphere. For cytotoxicity measurements, 10 μl 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT) solution (Sigma) was added to each well according to manufacturer’s instructions and analysed in a spectrophotometer at 580 nm.

NZX cytotoxicity was further examined by PrestoBlue® and ATPLite™ assays. Primary macrophages were treated with 100 μM NZX or 50 μM Staurosporine (S-4400, Sigma) for 24 h. Cell viability was compared with PrestoBlue® fluorescence (A13261, Thermo Scientific) and cellular ATP levels using ATPLite™ kit (6016943, Perkin Elmer) compared to untreated controls, according to the manufacturer’s instructions.

NF-kB activation was measured in human THP-1 XBlue™-CD14 monocytes following addition of 12.5 μM NZX or 10 ng/ml LPS as positive control. QUANTI-Blue™ assay was performed according to manufacturer’s instructions (Invivogen, San Diego, USA). Briefly, supernatants from the cells were added to QUANTI-Blue™ substrate for 1h and absorbance was measured at 620 nm. In parallel, the ATPLite™ assay was performed to ensure that the activation was not due to toxicity.

2.6. Protease sensitivity assay

NZX (1 μg) was incubated at 37 °C with human neutrophil elastase (HNE, 20 μg/ml, EMD Millipore) and human α-thrombin (20 μg/ml Innovative research) for 6h. The materials were analysed on 10–20% precast SDS-PAGE Tris-Tricine gels (LifeTechnologies) and stained with Coomassie Blue R-250.

2.7. MIC

To assess NZX for anti-mycobacterial activity we measured the minimal inhibitory concentration (MIC) against three strains of M. tuberculosis (H37Rv and the clinical isolate 1 (TB1298) and the clinical MDR isolate (TB4001)) using the MGIT960-culture system (BACTEC M. tuberculosis) (H37Rv via the intranasal route according to institutional protocols [31]. Mice were infected by intra-tracheal administration. The control group received 50 μl PBS by the same route. As an additional treatment control, five mice were dosed intra-tracheally with rifampicin at a concentration of 20 mg/kg for 5 days. An additional group of mice (n = 5) was treated with gold-labelled NZX. Following treatment, mice were euthanized to determine the actual dose implanted in the lungs. Five mice from the control group were euthanized prior to the start of treatment in order to determine the bacterial load in the lungs. Following 19 days of infection, the NZX groups were treated for five consecutive days with 0.83 mg NZX (33 mg/kg) diluted in 50 μl PBS by the same route. As an additional treatment control, five mice were dosed intra-tracheally with rifampicin at a concentration of 20 mg/kg for 5 days. An additional group of mice (n = 5) was treated with gold-labelled NZX. Following treatment, mice were culled and the lungs were aseptically removed. The left lobe of the lung was placed in 10% buffered formalin for 24h, for histology. The remaining tissue were homogenized in PBS containing 0.05% Tween-80, serially diluted and plated on Middlebrook 7H11 agar plates supplemented with 0.5% glycerol and 10% OADC. The number of CFU from all mice was enumerated 21 days later.

2.11. Histology and immunohistochemistry

Formalin fixed tissue was transferred to 70% ethanol overnight, then embedded and frozen in optimal cutting temperature compound (Sakura Finetek USA) for cryosectioning (8 μm; Leica microscope). Sections were collected on positively charged microscope slides (SuperFrost/Plus, Thermo Fisher Scientific), fixed in acetone-methanol (1:1, 10 min), dried, permeabilized (0.2% Triton X-100, 5% normal goat serum/PBS), and stained with primary rat anti-neutrophil antibody (NIMP-R14) (1:200; Abcam, ab25557), rabbit monoclonal anti-M. tuberculosis antibody (1:100; LIONEX, NB200-5799) and mouse anti-neutrophil (1:50; Abcam, ab119352), followed by Alexa 488 or Alexa 568-labeled rabbit anti-rat or goat anti-mouse immunoglobulin G secondary antibodies (Molecular Probes; A-21210, A-11001, and A-11011). Nuclei were counterstained with DAPI (4’,6-diamidino-2-phenylindole) (0.05 mM; Sigma-Aldrich). Slides were examined by fluorescence microscopy (AX60, Olympus Optical). Richard-Allan Scientific Signature Series Hematoxylin 7211 and Eosin-Y 7111 (Thermo Scientific) were used to counterstain the tissue sections.
2.12. Transmission electron microscopy

Lung samples from infected mice treated with gold-labelled NZX and gold treated controls were embedded in Epon 812 resin according to routine protocols [32]. Specimens were observed in a Philips/FEI CM100 transmission electron microscope (Philips, Eindhoven, Holland) operated at 80kV accelerating voltage, and images were recorded with a side-mounted Olympus Veleta camera (Olympus, Münster, Germany) with a resolution of 2048×2048 pixels.

2.13. Statistical analysis

Graphs and statistics were generated using the Prism software (version 6.1). Significance, where indicated, was calculated using the unpaired Student's t-test or ANOVA. For the bacterial growth inhibition screening tests, ANOVA followed by Dunnett's multiple comparison between NZX and the other peptides were performed. For the murine experiments based on two groups, untreated and treated, we analysed first the results for normal distribution (Shapiro-Wilk test) and then performed Student's t-test as recommended by Festing et al. and Morgan et al., [33,34]. For the murine experiment comparing three groups, untreated and treated with NZX of rifampicin, we performed ANOVA followed by Dunnett's multiple comparison and Mann-Whitney between groups. Significance was accepted at *p < 0.05, **p < 0.01, or ***p < 0.001.

Table 2
NZX MIC values determined for different mycobacteria spp. and clinical isolates.

<table>
<thead>
<tr>
<th>Mycobacteria</th>
<th>MIC (μM)</th>
<th>Mean (± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>H37Rv</td>
<td>6.3</td>
<td>3.4</td>
</tr>
<tr>
<td>Clinical isolate 1</td>
<td>5.3</td>
<td>1.8</td>
</tr>
<tr>
<td>Clinical isolate 2</td>
<td>3.2</td>
<td>0</td>
</tr>
<tr>
<td>Clinical MDR isolate</td>
<td>6.3</td>
<td>0</td>
</tr>
<tr>
<td>M. smegmatis</td>
<td>6.3</td>
<td>0</td>
</tr>
<tr>
<td>BCG</td>
<td>6.3</td>
<td>4.7</td>
</tr>
</tbody>
</table>

* Experiments were repeated three times for each strain.

2.14. Study approval

The animal studies have been approved (PPL 70/7160 and 70/8653) by the Local Animal Welfare and Ethical Review Board (London, UK). The Local Ethical Review Board Dnr 2011/403 and 2014/35 approved the donation of blood from human volunteers for the in vitro studies (Lund, Sweden), and the Lund district court approved the control animal studies (Dnr M 7–15). The blood for monocyte isolation for the toxicity analysis was donated by healthy volunteers (Local Ethical Review Board Dnr 2011/403 and 2014/35). No personal data was collected from the volunteers and the blood was pooled for the isolation of the monocytes. For the intracellular assays, human donor blood was purchased from the blood bank of Linköping University hospitals and blood donors gave written informed consent for research use of the blood.
3. Results

3.1. NZX demonstrates anti-mycobacterial activity

We investigated six peptides (Table 1) of which four were previously reported to possess activity against *M. tuberculosis* in vitro or in vivo [16]. We evaluated peptide toxicity against primary human macrophages (Fig. 1A) and peptide dose response curves against BCG (Fig. 1B). Of the peptides tested, LL-37 is the best-known antimicrobial compound and was used as a benchmark for the other peptides. At the lowest concentration tested (6.3μM) LL-37 inhibited up to 9.7% of mycobacteria growth (Fig. 1B) but was toxic at higher concentrations (Fig. 1A).

The peptide WKWLKKWIKG, previously shown to kill mycobacteria [14], was tested in three different versions (Table 1). Of these, WKK-LKKWIKG-NH₂xHOAc showed the best activity. At a concentration of 6.3μM, this peptide inhibited 19.2% of the mycobacterial growth, showing dose-dependent inhibition (Fig. 1B). The toxicity analysis revealed that peptide version WKWLKKWIKG-OHxTFA was least toxic to primary macrophages, but bacterial killing capacity was overall lower than that of WKWLKKWIKG-NH₂xHOAc. The peptides WKWLKKWIKG-NH₂xHOAc and WKWLKKWIKG-NH₂xTFA showed dose-dependent toxicity to macrophages, similar to LL-37 (Fig. 1B) but was toxic at higher concentrations (Fig. 1A).

The best antimicrobial activity was obtained with the plectasin derivatives NZ2114 and NZX, which both possessed high mycobacterial inhibitory capacity after 24h of incubation (Fig. 1A). The toxicity analysis revealed that peptide version WKWLKKWIKG-OHxTFA was least toxic to primary macrophages, but bacterial killing capacity was overall lower than that of WKWLKKWIKG-NH₂xHOAc. The peptides WKWLKKWIKG-NH₂xHOAc and WKWLKKWIKG-NH₂xTFA showed dose-dependent toxicity to macrophages, similar to LL-37 (Fig. 1A).

The best antimicrobial activity was obtained with the plectasin derivatives NZ2114 and NZX, which both possessed high mycobacterial inhibitory capacity after 24h of incubation (Fig. 1A). Furthermore, the toxicity analysis revealed that NZX was less toxic to human cells than LL-37 or the W-rich peptides (Fig. 1A). Comparing the two plectasin derivatives, NZX was the most effective as this peptide inhibited up to 74% of the mycobacterial growth at a concentration of 6.3μM (Fig. 1B).

3.2. NZX inhibits *M. tuberculosis*

*E. Tenland et al.* Tuberculosis 113 (2018) 231–238

6.3μM and 3.2μM for two clinical *M. tuberculosis* isolates (clinical isolate 1 and 2) and 6.3μM for the clinical MDR isolate (Table 2). The MIC concentrations for BCG and *M. smegmatis* were also 6.3μM. The potency of NZX compared to front-line drugs, ethambutol, rifampicin and isoniazid are shown in Supplementary Table 1. The time kill assay revealed that a single dose of NZX at 1.6 or 3.2μM killed BCG at days eleven and eight respectively (Fig. 2A). This assay also indicated that low doses of NZX could kill BCG. The influence of NZX on mycobacterial growth was further analysed by growth kinetics of NZX treated *M. tuberculosis* H37Rv (Fig. 2B). NZX treatment induced concentration-dependent reduction of initial bacterial growth.

3.3. NZX is not toxic to human cells

As several AMPs have been reported as toxic in vitro [35], we further investigated if NZX showed cytocidal effects on human cells. No toxicity was detected for NZX concentrations up to 100μM in any of the three assays (Fig. 3A–C). In addition, analysis of NF-κB activation after exposure of a monocyte cell line to NZX, revealed that the peptide does not induce inflammation (Fig. 3D).

3.4. NZX is resistant to degradation by proteases

A major barrier limiting the clinical application of AMPs is their susceptibility to degradation in biological fluids, by proteases such as the neutrophil elastase [36]. To investigate NZX stability, the peptide was incubated with human neutrophil elastase (HNE), cathepsin G and human α-thrombin. Of the investigated proteases, only HNE at a concentration of 20μg/ml degraded the NZX peptide, with approximately 33% breakdown after 6 h (Fig. 3E).

3.5. NZX induces intracellular killing of virulent *M. tuberculosis*

Intracellular anti-mycobacterial capacity of NZX was determined after 6 days using primary human macrophages infected with *M.
tuberculosis H37Rv. NZX mediated a concentration-dependent reduction in intracellular bacterial load with a maximum of 45% at 50 μM (Fig. 4A). Isoniazid (0.1 μg/ml, 0.7 μM), used as a positive control, resulted in the same intracellular killing as 50 μM of NZX (not shown). For in vivo experiments, NZX was labelled with gold particles and used to treat M. tuberculosis H37Rv infected mice. TEM visualization of sections from murine lungs demonstrated the presence of NZX on M. tuberculosis within macrophages (Fig. 4B). Gold particles without NZX was used as control to treat M. tuberculosis infected mice, but no gold particles were found in the lungs (data not shown).

3.6. NZX treatment efficacy in the M. tuberculosis mouse infection model

Bactericidal activity experiments were performed in a murine TB model with M. tuberculosis H37Rv and repeated two times [31] (Fig. 5A and B). The mean bacterial implantation dose in the lungs, measured two days after infection, was 677 CFU/ml, and the animals received five doses of NZX or rifampicin through intra-tracheal administration. In both experiments, we observed an CFU reduction by 46% after five days (Fig. 5A, p = 0.0079) in the lungs of mice treated with NZX compared to the control animals. Comparing the untreated group with NZX group or rifampicin group, we found significant differences (p < 0.001). Both rifampicin and NZX were significantly lower compared to untreated control (p = 0.0079 in both), and we found no significant difference between rifampicin and NZX treatment (p = 0.0556).

3.7. NZX preserves alveolar structure during acute tuberculosis

NZX treatment abrogated tissue destruction in infected mice as shown by immunohistochemistry (Fig. 5C). Lung tissue sections from NZX treated M. tuberculosis-infected mice showed less tissue damage, with lower bacterial and neutrophil counts than infected controls. Reduced inflammation and preserved alveolar structure was further confirmed by hematoxylin and eosin staining, which showed cellular infiltrates and consolidation of the lung in infected but untreated lungs, both of which were absent in the lungs of NZX-treated animals (Fig. 5C).
4. Discussion

The present study has identified a non-human peptide, NZX, that inhibits *M. tuberculosis* in vitro at concentrations comparable with standard anti-mycobacterial drugs [37]. Our murine TB model supports these observations, indicating that NZX may be useful as an adjunct therapy to treat TB. Of the peptides investigated, NZX had highest capacity to inhibit mycobacterial growth at a low concentration and was found to be non-toxic even at high concentrations. Our study challenge though previous publications on LL-37 and the synthetic variants of tryptophan-rich peptides that were all reported to effectively eliminate *M. tuberculosis* at low concentrations [14,16,20]. This discrepancy could result from the cell lines and species of mycobacteria used in different studies. We followed the toxicity guidelines and used primary cells [36,38], with additional toxicity assays on NZX. For antimicrobial activity, this peptide was assayed against *M. tuberculosis* H37Rv, but also three clinical isolates, of which one was resistant to the first-line antibiotics rifampicin and isoniazid. MIC values were similar for all species and strains investigated including the fast-growing *M. smegmatis* and the bovine vaccine strain BCG.

Antimicrobial peptides are generally easily degradable, which could pose a treatment problem, but we demonstrated that NZX was not easily degraded by a range of proteases. In addition, NZX reduced the burden of *M. tuberculosis* in the lungs of infected mice, further evidence that NZX is not readily degraded in these compartments. Interestingly, Grosset et al. investigated early bacillary activity of the first-line TB drugs [39], and showed that after two days of rifampicin/isoniazid/pyrazinamide/ethambutol treatment the mean CFU counts were reduced by 0.25 log10 on day 2 and by 0.96 log10 on day 7. Applying the same calculations to our data, we observed a 0.45 log10 reduction of *M. tuberculosis* in the lungs after five days of NZX-treatment compared with the untreated mice. No statistical difference was obtained in this model studies. However, these data suggest that NZX could be a useful addition to the current drug regimen used to treat TB.

During the different stages of infection *M. tuberculosis* survives both intracellularly and extracellularly [40]. Susceptibility to first-line anti-TB drugs correlates poorly for *M. tuberculosis* residing in macrophages compared to extracellular bacteria [41,42]. In our study, NZX mediated a concentration-dependent reduction of intracellular *M. tuberculosis* and we observed gold-labelled NZX inside alveolar macrophages from *M. tuberculosis* infected mice. However, the antimycobacterial mechanism of NZX is yet unknown. NZ2114 and NZX contain the same cysteine residues as plectasin suggesting structural similarity. These peptides also share histidine residues with plectasin. At physiological conditions, these histidines are largely unprotonated and uncharged with weak lytic properties [43]. However, NZ2114 and NZX could kill mycobacteria by other mechanisms, as plectasin was found to specifically target cell wall precursors in *Staphylococcus aureus* by binding to the peptidoglycan precursor lipid II N-terminal amino groups [44]. Taken together with the toxicity data, NZX appears to be able to target intracellular bacteria without lysing human cells. We also observed that NZX by reducing bacterial load in the lungs of infected mice, dampened leukocyte recruitment, which probably lead to the observed preserved tissue integrity. Whether NZX has immunomodulatory effect, in addition to its activity towards *M. tuberculosis*, needs further investigation.

In this study, we present a novel AMP that effectively kills *M. tuberculosis* in vitro and decreases the bacterial load in a murine TB infection model. The MIC and therapeutic dosage were comparable in their effectiveness to conventional TB-antibiotics, with no evidence of toxicity in our model systems. In addition, we found evidence that NZX has intracellular activity towards *M. tuberculosis*, further supporting NZX as a possible future treatment candidate.

Conflicts of interest

All authors declare no conflict of interest.

Acknowledgements

GG conceived and designed the study. ET, NK, AR, SK, MM, MP, MD, MO and IG-M developed the methodology and acquired data. GG, ET, NK, ML and BR analysed and interpreted the data. GG, ET, BR, NK, AS, ML and ES wrote, reviewed, and/or revised the manuscript. NA provided administrative support. GG and ET supervised the study. All authors contributed significantly to the final version of the manuscript.

NK, IGM and BR thank the UK Medical Research Council for support in the MRC Centre for Molecular Bacteriology and Infection, Imperial College London. The research was funded by the Swedish Heart-Lung Foundation (20150733), Alfred Österlunds Foundation, Royal Physiographic Society of Lund, Swedish Research Council and European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement no 604182, FORMAMP-Innovative Nanoformulation of Antimicrobial Peptides to Treat Bacterial Infectious Diseases (http://ec.europa.eu.research). The funding sources had no involvement in this study.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.tube.2018.10.008.

References


